Teva Says Novartis Is 'Shielding' MS Drug IP From Challenges
Generic-drug giant Teva Pharmaceuticals has accused Novartis of withdrawing infringement proceedings to "shield" the validity of a pending patent linked to its blockbuster multiple sclerosis drug from being challenged in the...To view the full article, register now.
Already a subscriber? Click here to view full article